Chunting Qi
Shanghai, 201210, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model.
Journal: Acta pharmaceutica Sinica. B
Published: March 12, 2025
Repression of RIPK1 kinase by INPP5D inhibits expression of diverse proinflammatory mediators and late-onset Alzheimer's disease risk factors.
Journal: Immunity
Published: March 10, 2025
Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer.
Journal: Science advances
Published: November 22, 2023
Spermidine mediates acetylhypusination of RIPK1 to suppress diabetes onset and progression.
Journal: Nature cell biology
Published: November 09, 2023
Small molecule activators of TAK1 promotes its activity-dependent ubiquitination and TRAIL-mediated tumor cell death.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 21, 2023
Structure-based development of potent and selective type-II kinase inhibitors of RIPK1.
Journal: Acta pharmaceutica Sinica. B
Published: May 21, 2023
Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer.
Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer.
Journal: Journal of medicinal chemistry
Published: October 12, 2022
SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
Journal: Oncogene
Published: October 09, 2021
SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation.
Journal: Cell research
Published: August 05, 2021
Death-domain dimerization-mediated activation of RIPK1 controls necroptosis and RIPK1-dependent apoptosis.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 15, 2018
Last Updated: 09/26/2026